☆ 4.7 Meeting Abstract

Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer.

JOURNAL OF CLINICAL ONCOLOGY (2015)

期刊

JOURNAL OF CLINICAL ONCOLOGY

卷 33, 期 7, 页码 -

出版社

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/jco.2015.33.7_suppl.172

关键词

-

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Oncology

Advances in bio-immunotherapy for castration-resistant prostate cancer

Canling Lin, Yonghui Chen, Liji Shi, Huarong Lin, Hongmei Xia, Weihua Yin

Summary: Prostate cancer is a significant disease worldwide, and its incidence is increasing in China. Despite the efficacy of chemotherapy agents, treatment failure can occur, leading to castration-resistant prostate cancer. Due to limited treatment options, bio-immunotherapy targeting the prostate microenvironment has become an important option for advanced prostate cancer. This study investigates the role of three types of bio-immunotherapies in castrate-resistant prostate cancer, providing insights for clinical treatment.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

The gut microbiome and efficacy of cancer immunotherapy

Giandomenico Roviello, Luigi Francesco Iannone, Melissa Bersanelli, Enrico Mini, Martina Catalano

Summary: Immunotherapy has revolutionized cancer treatment, but reliable biomarkers for predicting treatment response are still unknown. Recent studies suggest that the gut microbiota may play a role in modulating the efficacy and toxicity of immunotherapy drugs.

PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Review Oncology

Immune Checkpoint Inhibitors in Prostate Cancer

Shobi Venkatachalam, Taylor R. McFarland, Neeraj Agarwal, Umang Swami

Summary: Metastatic prostate cancer is a lethal disease with limited treatment options. Immune checkpoint inhibitors have revolutionized the treatment landscape in various cancer types, but have not been as successful in prostate cancer. This review discusses the preclinical rationale and barriers inhibiting the effectiveness of immunotherapy in prostate cancer, as well as the ongoing studies evaluating the use of immune checkpoint inhibitors in combination with other agents to improve treatment outcomes.

CANCERS (2021)

添加到收藏夹

Review Immunology

Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer

Arthur Mulvey, Emilien Muggeo-Bertin, Dominik R. Berthold, Fernanda G. Herrera

Summary: This article reviews the role of immunotherapy in prostate cancer, discusses opportunities for future development, and explores the potential of synergistic therapeutic strategies with modern radiotherapy.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Review Medicine, Research & Experimental

The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer

Hajar Alemohammad, Basira Najafzadeh, Zahra Asadzadeh, Amir Baghbanzadeh, Farid Ghorbaninezhad, Arezoo Najafzadeh, Hossein Safarpour, Renato Bernardini, Oronzo Brunetti, Margherita Sonnessa, Rossella Fasano, Nicola Silvestris, Behzad Baradaran

Summary: The growth and development of cancer are directly correlated to the suppression of the immune system, with immune checkpoints playing a key role in inhibiting anti-tumor immune responses. Up-regulation of inhibitory immune checkpoints on immune cells during tumor progression suppresses anti-tumor immune responses and promotes immune escape. Targeting inhibitory immune checkpoints through antibodies or miRNAs is a promising therapeutic strategy, and immune checkpoint inhibitors have shown favorable results in enhancing immune cell-induced antitumor responses.

BIOMEDICINE & PHARMACOTHERAPY (2022)

添加到收藏夹

Article Oncology

Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG

Anne Zaremba, Peter Mohr, Ralf Gutzmer, Friedegund Meier, Claudia Pfoehler, Michael Weichenthal, Patrick Terheyden, Andrea Forschner, Ulrike Leiter, Jens Ulrich, Jochen Utikal, Julia Welzel, Martin Kaatz, Christoffer Gebhardt, Rudolf Herbst, Anca Sindrilaru, Edgar Dippel, Michael Sachse, Frank Meiss, Lucie Heinzerling, Sebastian Haferkamp, Carsten Weishaupt, Harald Loeffler, Sophia Kreft, Klaus Griewank, Elisabeth Livingstone, Dirk Schadendorf, Selma Ugurel, Lisa Zimmer

Summary: This study analyzed the impact of NRAS gene mutations on melanoma patients treated with immune checkpoint inhibitors. The results showed that NRAS mutations were not significantly correlated with patients' survival and treatment response, and had no correlation with the expression of the T-cell immune checkpoint molecule PD-L1.

EUROPEAN JOURNAL OF CANCER (2023)

添加到收藏夹

Review Oncology

Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances

Miyad Movassaghi, Rainjade Chung, Christopher B. Anderson, Mark Stein, Yvonne Saenger, Izak Faiena

Summary: Immunotherapy in prostate cancer faces challenges due to multiple interrelated mechanisms affecting treatment efficacy. Various strategies are being tested to overcome immune resistance, including combining different classes of treatment modalities. Studies have shown that combining vaccines or checkpoint inhibitors with other therapies may enhance immune responses and induce long-lasting clinical responses.

CANCERS (2021)

添加到收藏夹

Review Oncology

Immune Checkpoint Inhibitors in Cancer Therapy-How to Overcome Drug Resistance?

Yefang Lao, Daoming Shen, Weili Zhang, Rui He, Min Jiang

Summary: Immune checkpoint inhibitors are an important strategy in cancer therapy, but some patients develop resistance to these inhibitors. Understanding the mechanisms of antitumor action and drug resistance is crucial to narrow down the population of resistant patients. This review discusses the antitumor action sites and mechanisms of different types of immune checkpoint inhibitors, as well as proposes current and future solutions for resistance.

CANCERS (2022)

添加到收藏夹

Review Oncology

Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review

Carly C. Barron, Isabella Stefanova, Yevin Cha, Karam Elsolh, Arman Zereshkian, Nessma Gaafour, Elaine McWhirter

Summary: Immune-related adverse events (irAEs) are toxicities resulting from use of immune checkpoint inhibitors (ICIs). These side effects persist in some patients despite withholding therapy and using immunosuppressive and immune-modulating agents. Little is known about chronic irAEs and they are felt to be rare.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹

Article Chemistry, Multidisciplinary

Chemotherapy-Induced Neoantigen Nanovaccines Enhance Checkpoint Blockade Cancer Immunotherapy

Guiyuan Chen, Xiangxia Li, Rui Li, Kecheng Wu, Zhouhang Lei, Ruike Dai, Kyle Roche, Andrew Z. Wang, Yuanzeng Min

Summary: Researchers hypothesized that treating cancer cells with ultrahigh doses of chemotherapeutics in vitro could artificially enhance the immunogenicity, thereby improving chemoimmunotherapy.

ACS NANO (2023)

添加到收藏夹

Article Oncology

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients

A. Bessede, A. Marabelle, J. P. Guegan, F. X. Danlos, S. Cousin, F. Peyraud, N. Chaput, M. Spalato, G. Roubaud, M. Cabart, M. Khettab, A. Chaibi, C. Rey, I Nafia, F. X. Mahon, J. C. Soria, A. Italiano

Summary: The study reveals that acetaminophen (APAP) may suppress antitumor immunity and impact the efficacy of immunotherapy in cancer patients.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors

Rom Leidner, Kevin Conlon, Douglas G. Mcneel, Andrea Wang-Gillam, Sumati Gupta, Robert Wesolowski, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Lang Ho Lee, Jessica A. O'Keeffe, Nancy Lewis, George N. Pavlakis, John A. Thompson

Summary: This study investigated the efficacy and safety of NIZ985 as monotherapy and in combination with spartalizumab in the treatment of advanced solid tumors. The results showed that NIZ985 demonstrated antitumor activity and was well tolerated in patients with advanced solid tumors.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹

Review Immunology

Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis

Maryam Noori, Shadi Azizi, Aref Mahjoubfar, Farhan Abbasi Varaki, Farimah Fayyaz, Amir-Hossein Mousavian, Davood Bashash, Mehdi Kardoust Parizi, Amir Kasaeian

Summary: This study evaluated the efficacy and safety of immune checkpoint inhibitors (ICIs) in prostate cancer patients through a systematic review and meta-analysis. The findings showed varying median overall survival (mOS) for different treatment regimens, with the lowest incidence of adverse events in the anti-PD-1/PD-L1 monotherapy group. Future studies should focus on evaluating the efficacy and safety of novel combination therapies with ICIs.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Immunology

Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment

Ying Wang, Mengxue Yang, Mingyang Tao, Peipei Liu, Cheng Kong, Hao Li, Yingmei Chen, Xudong Yin, Xuebing Yan

Summary: The use of corticosteroids for cancer-related indications in lung cancer patients receiving ICI treatment is associated with poorer prognosis, as demonstrated by meta-analysis and retrospective analysis. Subgroup analysis focusing on non-small cell lung cancer (NSCLC) showed similar results, highlighting the importance of careful selection of corticosteroid-treated patients for ICI therapy in personalized clinical management.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Nanomedicine for Combination Urologic Cancer Immunotherapy

Yun Tian, Zhenzhu Liu, Jianbo Wang, Linan Li, Fuli Wang, Zheng Zhu, Xuejian Wang

Summary: Urologic cancers, such as kidney, bladder, and prostate cancer, have a growing incidence and cause a significant number of deaths worldwide. Immunotherapy, including immunological checkpoint blockade, non-specific activation of the immune system, adoptive cell therapy, and tumor vaccine, shows promise but faces challenges in terms of toxicities and response rates. Nanomaterial-based platforms offer solutions by combining nanotechnology with immunotherapy, leading to precision medicine, improved efficacy, and reduced toxicities in urologic cancer treatment.

PHARMACEUTICS (2023)

添加到收藏夹

Article Oncology

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

Geraldine O'Sullivan Coyne, Shivaani Kummar, James Hu, Kristen Ganjoo, Warren A. Chow, Khanh T. Do, Jennifer Zlott, Ashley Bruns, Lawrence Rubinstein, Jared C. Foster, Lamin Juwara, Robert Meehan, Richard Piekarz, Howard Streicher, Elad Sharon, Naoko Takebe, Andrea Regier Voth, Donald Bottaro, Rene Costello, John J. Wright, James H. Doroshow, Alice P. Chen

Summary: In this study, the efficacy of single-agent cabozantinib in treating advanced soft-tissue sarcomas (STS) was evaluated. The results showed that cabozantinib exhibited antitumor activity in selected STS histologic subtypes, highlighting the biomolecular diversity of STS.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Review Oncology

Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment

James L. Gulley, Jeffrey Schlom, Mary Helen Barcellos-Hoff, Xiao-Jing Wang, Joan Seoane, Francois Audhuy, Yan Lan, Isabelle Dussault, Aristidis Moustakas

Summary: Transforming growth factor-beta (TGF-beta) and programmed death-ligand 1 (PD-L1) have immunosuppressive functions in the tumor microenvironment (TME) and inhibiting these pathways can improve clinical outcomes and reduce toxicity.

MOLECULAR ONCOLOGY (2022)

添加到收藏夹

Article Oncology

A Randomized Phase II Trial of mFOLFOX6+Bevacizumab Alone or with AdCEA Vaccine plus Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer

Jason M. Redman, Yo-Ting Tsai, Benjamin A. Weinberg, Renee N. Donahue, Shruti Gandhy, Margaret E. Gatti-Mays, Houssein Abdul Sater, Marijo Bilusic, Lisa M. Cordes, Seth M. Steinberg, Jennifer L. Marte, Caroline Jochems, Sunnie S. Kim, John L. Marshall, Sheri McMahon, Erica Redmond, Jeffrey Schlom, James L. Gulley, Julius Strauss

Summary: This study compared the effectiveness of the standard of care with and without the addition of Avelumab and AdCEA vaccine in the treatment of metastatic colorectal cancer. The results showed that while the combination treatment generated a multifunctional immune response, it did not improve progression-free survival. Additional agents may be required to enhance the clinical benefit.

ONCOLOGIST (2022)

添加到收藏夹

Article Oncology

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma

James Nguyen, Naoko Takebe, Shivaani Kummar, Albiruni Razak, Sant P. Chawla, Suzanne George, Shreyaskumar R. Patel, Mary Louise Keohan, Sujana Movva, Geraldine O. 'Sullivan Coyne, Khanh Do, Lamin Juwara, Brooke Augustine, Seth M. Steinberg, Laura Kuhlmann, S. Percy Ivy, James H. Doroshow, Alice P. Chen

Summary: This phase II randomized trial aimed to evaluate the activity and tolerability of single-agent cediranib or sunitinib in patients with advanced metastatic alveolar soft part sarcoma (ASPS). The results showed that both drugs provided clinical benefit, but the response rates may have been affected by the time of disease progression.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Article Oncology

Phase 1 trial of CV301 in combination with anti-PD-1 therapy in nonsquamous non-small cell lung cancer

Arun Rajan, Jhanelle E. Gray, Siddhartha Devarakonda, Ruemu Birhiray, Borys Korchin, Erika Menius, Renee N. Donahue, Jeffrey Schlom, James L. Gulley

Summary: CV301 in combination with PD-1 inhibitors is safe and clinically active in advanced NSCLC patients, without an increased frequency or severity of immune-related adverse events.

INTERNATIONAL JOURNAL OF CANCER (2023)

添加到收藏夹

Article Oncology

Effect of CD4+T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer

Thomas A. Odeny, Kathryn Lurain, Julius Strauss, Steven P. Fling, Elad Sharon, Anna Wright, Javier Martinez-Picado, Teresa Moran, James L. Gulley, Maria Gonzalez-Cao, Thomas S. Uldrick, Robert Yarchoan, Ramya Ramaswami

Summary: There was no significant difference in the baseline CD4 counts or the proportions of any TEAE and grade ≥ 3 TEAE between HIV-positive and HIV-negative patients receiving immune checkpoint inhibitor (ICI) treatment. CD4 count thresholds for cancer clinical trials should be carefully reviewed to avoid unnecessarily excluding patients with HIV and cancer.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Review Oncology

Molecular Pathways and Mechanisms of TGFb in Cancer Therapy

Mary Helen Barcellos-Hoff, James L. Gulley

Summary: Despite the increasing number of TGFI3 inhibitors tested in cancer patients, there has been no clinical benefit achieved yet. The main obstacle to effective TGFI3 inhibition is the diverse mechanisms by which TGFI3 promotes tumor growth. TGFI3 is involved in regulating DNA repair and immune suppression, which can be used to synergize genotoxic therapy and immunotherapy for the benefit of cancer patients.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation

Cody J. Peer, Keith T. Schmidt, Oluwatobi Arisa, William J. Richardson, Koosha Paydary, Daniel A. Goldstein, James L. Gulley, William D. Figg, Mark J. Ratain

Summary: Atezolizumab, a humanized monoclonal antibody against PD-L1, was approved in 2016. Standard dose regimens result in high plasma concentrations, indicating the need for alternative dosing strategies to reduce exposure burden.

JOURNAL OF CLINICAL PHARMACOLOGY (2023)

添加到收藏夹

Article Oncology

Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial

Alexander Spira, Michael S. Wertheim, Edward J. Kim, Benjamin Tan, Heinz-Josef Lenz, Petros Nikolinakos, Patricia L. Rich, Genevieve Jehl, Andreas Machl, Rena Ito, James L. Gulley, Scott Kopetz

Summary: A phase I study on bintrafusp alfa in heavily pretreated patients with colorectal cancer showed promising early signs of clinical efficacy and manageable safety profile.

ONCOLOGIST (2023)

添加到收藏夹

Article Oncology

A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors

Margaret E. Gatti-Mays, Nicholas P. Tschernia, Julius Strauss, Ravi A. Madan, Fatima H. Karzai, Marijo Bilusic, Jason Redman, Houssein Abdul Sater, Charalampos S. Floudas, Nicole J. Toney, Renee N. Donahue, Caroline Jochems, Jennifer L. Marte, Deneise Francis, Sheri McMahon, Elizabeth Lamping, Lisa Cordes, Jeffrey Schlom, James L. Gulley

Summary: The results of this study showed that biweekly NHS-IL12 treatment was safe for patients with advanced cancers. NHS-IL12 is a first-in-class fusion protein used in this trial. Patients received NHS-IL12 every two weeks, and the results demonstrated stable disease status for the patients.

ONCOLOGIST (2023)

添加到收藏夹

Article Oncology

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer

Emerson A. Lim, Michael T. Schweizer, Kim N. Chi, Rahul Aggarwal, Neeraj Agarwal, James Gulley, Edward Attiyeh, James Greger, Shujian Wu, Pharavee Jaiprasart, John Loffredo, Nibedita Bandyopadhyay, Hong Xie, Aaron R. Hansen

Summary: PSMA expression is maintained in all stages of prostate cancer. In a phase 1 study, a bispecific antibody targeting PSMA-expressing tumor cells and CD3-expressing T cells showed manageable cytokine release syndrome and temporary decline in PSA in patients with metastatic castration-resistant prostate cancer. Treatment-related deaths and radiographic responses were not observed. PSMA is a potential therapeutic target for T-cell redirection in prostate cancer.

CLINICAL GENITOURINARY CANCER (2023)

添加到收藏夹

Article Oncology

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies

Michael B. Atkins, Paolo A. Ascierto, David Feltquate, James L. Gulley, Douglas B. Johnson, Nikhil Khushalani, Jeffrey Sosman, Timonthy A. Yap, Harriet Kluger, Ryan J. Sullivan, Hussein Tawbi

Summary: Immunotherapy alone does not work for all tumors, so combining it with signal transduction inhibitors, such as antiangiogenic therapies, can enhance its effectiveness. Combination therapies with immunotherapy have shown improved antitumor activity in various solid tumor settings and have received regulatory approval for the treatment of several types of cancer. However, many patients still experience progression after combination treatment, highlighting the need for new strategies to address resistance to immunotherapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹

Review Oncology

Vaccinating against cancer: getting to prime time

Ryan Chang, James L. Gulley, Lawrence Fong

Summary: Immunotherapies, such as immune checkpoint inhibitors and cellular therapies, have revolutionized cancer treatment, but the development of successful cancer vaccines remains challenging. Only two vaccines have shown improved survival in advanced disease: sipuleucel-T and talimogene laherparepvec, which target specific antigens and utilize tumors in situ to prime responses. In this review, we examine the challenges and opportunities in developing therapeutic cancer vaccines.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹

Meeting Abstract Oncology

Phase II evaluation of the combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16+malignancies

Julius Strauss, Charalampos S. Floudas, Danielle M. Pastor, Michell Manu, Elizabeth Lamping, Deneise C. Francis, Lisa M. Cordes, Jenn Marte, Renee Nicole Donahue, Caroline Jochems, Scott Norberg, Jason Redman, Fatima Karzai, Ravi Amrit Madan, Jeffrey Schlom, James L. Gulley

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

A phase I trial of T-cell receptor gene therapy targeting KK-LC-1 for gastric, breast, cervical, lung and other KK-LC-1 positive epithelial cancers

Scott Norberg, Erika Maria Von Euw, Gordon Parry, Steven Highfill, Zulmarie Franco, James L. Gulley, Christian S. Hinrichs

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.